Status:
COMPLETED
Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis
Lead Sponsor:
Ghurki Trust and Teaching Hospital
Conditions:
Psoriasis
Eligibility:
All Genders
18-59 years
Phase:
PHASE4
Brief Summary
Psoriasis is a persistent condition which demands prolonged management, so it puts heavy financial as well as psychological burden on patients. Severe psoriasis makes work impossible for patients. If ...
Eligibility Criteria
Inclusion
- Age between 18-59 years
- Both genders
- Diagnosed patient of Psoriasis
- Moderate to severe psoriasis
- Not responding to topical treatment
- Not responding to conventional systemic treatments i.e., methotrexate, cyclosporine and phototherapy.
- PASI score \>10.
Exclusion
- Patient with active systemic lupus erythematosus or ANA positive patients.
- Patient with active tuberculosis.
- Extremely immunocompromised patient.
- Patient with cardiac disease.
- Patient with allergic reaction to REMSIMA.
- Pregnancy and Lactation.
Key Trial Info
Start Date :
March 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 5 2023
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT06043752
Start Date
March 10 2022
End Date
August 5 2023
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ghurki Hospital
Lahore, Punjab Province, Pakistan